The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa

Journal of the International AIDS Society

Volumn 15, Issue 1, 2012, Pages

  Ataher, Quazi ^a   Portsmouth, Simon ^a   Napolitano, Laura A ^b   Eng, Sybil ^a   Greenacre, Anna ^a   Kambugu, Andrew ^c   Wood, Robin ^d   Badal Faesen, Sharlaa ^e   Tressler, Randy ^a  

^a PFIZER INC   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e HELEN JOSEPH HOSPITAL   (South Africa)

Author keywords

CCR5 (R5); cellular factors; co receptor; CXCR4 (X4); HIV 1 clade; HIV 1 subtype; tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; VIRUS RECEPTOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SOUTH AFRICA; UGANDA; VIRUS LOAD; CLASSIFICATION; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN BINDING; VIRAL TROPISM; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN BINDING; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, VIRUS; SOUTH AFRICA; UGANDA; VIRAL TROPISM; YOUNG ADULT;

EID: 84856082773     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-15-2     Document Type: Article

References (48)

1. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Thomson MM, Perez-Alvarez L, Najera R, Lancet Infect Dis 2002 2 461 471 10.1016/S1473-3099(02)00343-2 12150845 (Pubitemid 34826851)
2. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. Buonaguro L, Tornesello ML, Buonaguro FM, J Virol 2007 81 10209 10219 10.1128/JVI.00872-07 17634242 (Pubitemid 47463296)
3. HIV diversity, molecular epidemiology, and the role of recombination. Kijak GH, McCutchan FE, Curr Infect Dis Rep 2005 7 480 488 10.1007/s11908-005- 0051-8 16225787 (Pubitemid 41671592)
4. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J, J Infect Dis 2002 185 1244 1250 10.1086/340130 12001041 (Pubitemid 34439131)
5. What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. Hu DJ, Buve A, Baggs J, van der GG, Dondero TJ, AIDS 1999 13 873 881 10.1097/00002030-199905280-00002 10475680 (Pubitemid 29240181)
6. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG, J Antimicrob Chemother 2003 51 229 240 10.1093/jac/dkg079 12562686 (Pubitemid 36231141)
7. Human immunodeficiency virus-1 subtypes: could genetic diversity translate to differential pathogenesis. Ranga U, J Indian Inst Sci 2002 82 73 91
8. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. Cornelissen M, Mulder-Kampinga G, Veenstra J, Zorgdrager F, Kuiken C, Hartman S, Dekker J, van der HL, Sol C, Coutinho R, J Virol 1995 69 1810 1818 7853521
9. Predictors of rapid progression to AIDS in HIV-1 seroconverters. Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, Goudsmit J, Coutinho RA, AIDS 1993 7 51 57 10.1097/00002030-199301000-00008 8095146 (Pubitemid 23069032)
10. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J, AIDS 1993 7 1035 1040 10.1097/00002030-199308000-00002 8104421 (Pubitemid 23246445)
11. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR, J Infect Dis 2005 192 466 474 10.1086/431519 15995960 (Pubitemid 41023125)
12. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG, J Infect Dis 2005 191 866 872 10.1086/428096 15717260 (Pubitemid 40349800)
13. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. Moore JP, Kitchen SG, Pugach P, Zack JA, AIDS Res Hum Retroviruses 2004 20 111 126 10.1089/088922204322749567 15000703 (Pubitemid 38147183)
14. Assessing chemokine co-receptor usage in HIV. Coakley E, Petropoulos CJ, Whitcomb JM, Curr Opin Infect Dis 2005 18 9 15 10.1097/00001432-200502000-00003 15647694 (Pubitemid 41716234)
15. Association between CCR5 genotype and the clinical course of HIV-1 infection. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Miedema F, Goudsmit J, Schuitemaker H, Ann Intern Med 1997 127 882 890 9382366 (Pubitemid 27490625)
16. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, Schuitemaker H, Fontanet AL, Rinke de Wit TF, AIDS 1999 13 1305 1311 10.1097/00002030-199907300-00006 10449282 (Pubitemid 29408444)
17. HIV-1 subtype and second-receptor use. Zhang L, Huang Y, He T, Cao Y, Ho DD, Nature 1996 383 768 10.1038/383768a0 8892998 (Pubitemid 26372652)
18. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng R, Matton T, Molinier S, Delaporte E, J Acquir Immune Defic Syndr Hum Retrovirol 1999 20 115 121 10.1097/00042560-199902010-00002 10048897 (Pubitemid 29063708)
19. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). Chen Z, Huang Y, Zhao X, Skulsky E, Lin D, Ip J, Gettie A, Ho DD, J Virol 2000 74 6501 6510 10.1128/JVI.74.14.6501-6510.2000 10864663 (Pubitemid 30429818)
20. Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. Lin NH, Smeaton LM, Giguel F, Novitsky V, Moyo S, Mitchell RM, Makhema J, Essex M, Lockman S, Kuritzkes DR, J Acquir Immune Defic Syndr 2011 57 46 50 10.1097/QAI.0b013e318214fe27 21346588
21. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Tscherning C, Alaeus A, Fredriksson R, Bjorndal A, Deng H, Littman DR, Fenyo EM, Albert J, Virology 1998 241 181 188 10.1006/viro.1997.8980 9499793 (Pubitemid 28384191)
22. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ, J Virol 2007 81 7885 7893 10.1128/JVI.00218-07 17507467 (Pubitemid 47101474)
23. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, Morgan D, Beddows S, Weber J, Whitworth JA, J Acquir Immune Defic Syndr 2007 45 28 33 10.1097/QAI. 0b013e3180385aa0 17310935 (Pubitemid 46684440)
24. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development. Zhang C, Xu S, Wei J, Guo H, Int J Infect Dis 2009 13 212 e216 10.1016/j.ijid.2008.12.010 19217335
25. Maraviroc for previously treated patients with R5 HIV-1 infection. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, N Engl J Med 2008 359 1429 1441 10.1056/NEJMoa0803152 18832244
26. Travel and the spread of HIV-1 genetic variants. Perrin L, Kaiser L, Yerly S, Lancet Infect Dis 2003 3 22 27 10.1016/S1473-3099(03)00484-5 12505029 (Pubitemid 36041785)
27. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR, AIDS 2010 24 2517 2525 10.1097/QAD.0b013e32833e6cfb 20736814
28. Portsmouth S, Chapman D, Lewis M, Ataher Q, Greenacre A, Valdez V, Harrigan PR, Virologic Outcome by V3 Loop Genotypic Population Sequencing and 454 'Deep Sequencing' in Clade B and Non-B Virus in MERIT at 48 and 96 Weeks. 18 th International AIDS Conference, Vienna, Austria 2010
29. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ, Antimicrob Agents Chemother 2007 51 566 575 10.1128/AAC.00853-06 17116663 (Pubitemid 46185274)
30. Trofileco-receptor tropism assay. http://www.trofileassay.com
31. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM, J Viral Entry 2009 3 102
32. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD, J Infect Dis 2009 200 1724 1728 10.1086/648090 19874179
33. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E, Clin Infect Dis 2011 52 925 928 10.1093/cid/cir072 21427401
34. Re-analysis of the MERIT study with the enhanced Trofile assay (MERIT-ES). Saag M, Heera J, Goodrich J, DeJesus E, Clumeck N, Cooper D, Walmsley S, Ting N, Coakley E, Reeves J, Westby M, van der Ryst E, Mayer H, 48th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC 2008
35. Maraviroc versus efavirenz, both in combination with zidovudine- lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, DeJesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, van der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H, J Infect Dis 2010 201 803 813 10.1086/650697 20151839
36. World Health Organization, Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report; 2008
37. Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection. Dash PK, Siddappa NB, Mangaiarkarasi A, Mahendarkar AV, Roshan P, Anand KK, Mahadevan A, Satishchandra P, Shankar SK, Prasad VR, Ranga U, Retrovirology 2008 5 25 10.1186/1742-4690-5-25 18328091 (Pubitemid 351559281)
38. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza P, Kazembe P, Maida M, Zimba D, Goodenow MM, Eron JJ Jr, Fiscus SA, Cohen MS, Swanstrom R, J Virol 1999 73 6271 6281 10400718 (Pubitemid 29327803)
39. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari DA, Virology 2000 271 253 258 10.1006/viro.2000.0297 10860879 (Pubitemid 30461303)
40. Primary subtype C HIV-1 infection in Harare, Zimbabwe. Tien PC, Chiu T, Latif A, Ray S, Batra M, Contag CH, Zejena L, Mbizvo M, Delwart EL, Mullins JI, Katzenstein DA, J Acquir Immune Defic Syndr Hum Retrovirol 1999 20 147 153 10.1097/00042560-199902010-00006 10048901 (Pubitemid 29063712)
41. Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda. Kaleebu P, Whitworth J, Hamilton L, Rutebemberwa A, Lyagoba F, Morgan D, Duffield M, Biryahwaho B, Magambo B, Oram J, AIDS Res Hum Retroviruses 2000 16 393 401 10.1089/088922200309052 10772525 (Pubitemid 30193807)
42. Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. Yirrell DL, Kaleebu P, Morgan D, Watera C, Magambo B, Lyagoba F, Whitworth J, AIDS 2002 16 279 286 10.1097/00002030-200201250-00018 11807313 (Pubitemid 34118575)
43. The epidemiology of HIV coreceptor tropism. Hoffmann C, Eur J Med Res 2007 12 385 390 17933718
44. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM, Clin Infect Dis 2007 44 591 595 10.1086/511035 17243065 (Pubitemid 46233265)
45. Napolitano LA, Tressler R, Coakley E, Santos C, Heera J, Whitcomb J, Incorporation of optimized primers into the Trofile assay substantially improves determination of viral tropism in genetically diverse HIV subtypes. 49 th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 12-15 H-908 2009
46. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD, Science 1993 261 1179 1181 10.1126/science.8356453 8356453 (Pubitemid 23300886)
47. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Margolis L, Shattock R, Nat Rev Microbiol 2006 4 312 317 10.1038/nrmicro1387 16541138
48. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG, J Virol 2009 83 8208 8220 10.1128/JVI.00296-09 19515785